Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10281195 | 0.83 | MAPK1 (0.42) | CA1CA2MEN1KMT2AALDH1A1 | |
| SCHEMBL409808 | 0.77 | CA1 (0.41) | CA1CA2CCNA2CDK2HTR2A | |
| SCHEMBL12930022 | 0.77 | CYP2C9 (0.43) | CA1CA2CCNA2CDK2HTR2A | |
| SCHEMBL31042823 | 0.75 | CA1 (0.40) | CA1CA2CCNA2CDK2HTR2A | |
| SCHEMBL15748689 | 0.74 | CA1 (0.41) | CA1CA2CCNA2CDK2HTR2A | |
| SCHEMBL10227709 | 0.73 | CCNA2 (0.40) | CA1CA2CCNA2CDK2HTR2A | |
| SCHEMBL20680132 | 0.73 | CA1 (0.51) | CA1CA2CCNA2CDK2HTR2A | |
| SCHEMBL20680130 | 0.73 | CA1 (0.46) | CA1CA2CCNA2CDK2HTR2A | |
| SCHEMBL30832189 | 0.73 | CA1 (0.46) | CA1CA2CCNA2CDK2HTR2A | |
| SCHEMBL12930005 | 0.72 | MEN1 (0.46) | CA1CA2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240326030-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2024-10-03 | — | — | US | claimed |
| CN-118530144-A | Paen Jia preparation method of beach | 中国医学科学院药物研究所 | 2024-08-23 | — | — | CN | claimed |
| CN-115974856-A | Preparation method of medicine of vatistal for treating adult T cell leukemia lymphoma | 北京康立生医药技术开发有限公司 | 2023-04-18 | — | — | CN | claimed |
| EP-4737455-A1 | COMPOUND CONTAINING MULTI-FUSED RING STRUCTURE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260098037-A1 | COMPOUND CONTAINING MULTI-FUSED RING STRUCTURE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2026-04-09 | — | — | US | disclosed |
| US-20250153157-A1 | PALLADIUM PRECATALYST EMBODIMENTS FOR ENANTIOSELECTIVE CHEMICAL REACTIONS AND METHODS OF MAKING AND USING THE SAME | UVIC IND PARTNERSHIPS INC (CA) | 2025-05-15 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119546584-A | Bicyclic compounds and their use as pest control agents | PI工业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-119301129-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-8841487-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841487-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841487-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | CACNA1G 4673/4885CACNA1H 4775/4885CACNA1I 4682/4885 |
| US-20240326030-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | PDCD6IP, PDPK1, PDCD10 | CACNA1G 3454/4885CACNA1H 3709/4885CACNA1I 3747/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | CACNA1G 4628/4885CACNA1H 4582/4885CACNA1I 4767/4885 |
| US-20260098037-A1 | COMPOUND CONTAINING MULTI-FUSED RING STRUCTURE | SLC5A2, SLC5A11, SLC5A1 | CACNA1G 2367/4885CACNA1H 1728/4885CACNA1I 2447/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CACNA1G 4628/4885CACNA1H 4582/4885CACNA1I 4767/4885 |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | CACNA1G 4476/4885CACNA1H 4639/4885CACNA1I 4441/4885 |
| US-20250153157-A1 | PALLADIUM PRECATALYST EMBODIMENTS FOR ENANTIOSELECTIVE CHEMICAL REACTIONS AND METHODS OF MAKING AND USING THE SAME | PPOX, PDCD1, DDT | CACNA1G 4184/4885CACNA1H 4326/4885CACNA1I 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.